Refine by
Hiv 1 Articles & Analysis: Older
6 articles found
Vaccines are considered one of the most successful medical interventions in the past few centuries, aiming to harness the human immune system and generate lasting protection against specific diseases. Traditional vaccines rely on the use of inactivated pathogens to trigger an immune response. However, many of these formulations carry a high risk of causing allergies or autoimmune reactions. ...
Despite being recently covered by the global epidemic of COVID-19, humanity is still facing an epidemic of another disease, AIDS, with approximately 38 million people living with HIV worldwide, according to UNAIDS. Many people have died as a result of HIV infection since the epidemic began in the 1980s. Researchers from Germany have recently developed a new technique that may be able to ...
Why do we need new cell contenders in the CAR field? Well, different CAR immune cells have different advantages and sometimes unique challenges or limitations. So, we began our discussion of alternative CAR-cell types with CAR-NK cells due to their current standing as the most popular alternative CAR-based therapy. However, the expansion of CARs to other cell types has already begun and ...
Clinical efficacy, tolerability and safety of various doses of Iodine-Lithium-α-Dextrin (ILαD) monotherapy have been evaluated in 56 HIV-infected patients enrolled in double blind uncontrolled randomised study during 48 weeks follow-up period. ILαD was administered intravenously three times over five days with intervals of 23 weeks between treatments for a total of 12 infusions in 4 cycles. HIV-1 ...
India has more than 5 million people infected with HIV-1 and this number is likely to increase in coming years. It is estimated that by the turn of this decade more than 10 million people would have been infected with this virus. More than 90% of these infections are due to subtype C. Therefore, it is imperative that a vaccine be developed based on local circulating subtype and tested for ...
Many HIV-1 envelope-based synthetic peptides behave as antigenic mimics of linear or conformational epitopes generated in vivo in infected subjects, meaning they can be used as immunogens for antibody induction in appropriate animal models or as antigens in Enzyme-Linked Immunosorbent Assay (ELISA). These peptides are linear or branched, single sequenced or multi-epitopic, mostly representative ...